Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Cholesterol drug helps heart failure patients without high cholesterol


People with heart failure and normal cholesterol may benefit from cholesterol-lowering drugs called statins, researchers report in today’s rapid access issue of Circulation: Journal of the American Heart Association.

"This is the first prospective study to show that statins have beneficial effects in heart failure in the absence of coronary artery disease or high blood cholesterol," says senior author James K. Liao, M.D., director of vascular medicine research at Brigham & Women’s Hospital and associate professor of medicine at Harvard Medical School, Boston, Mass. "This was a surprising finding in that the benefits occur after only 14 weeks of treatment and with a very low dose of the drug."

Statins have already been shown to decrease the incidence of chronic heart failure in patients with coronary artery disease and high cholesterol. However, the effect of statins on heart failure in people without cholesterol-induced coronary artery disease is not known.

The improved heart function observed in this study was in addition to the improvement already observed with two current treatments for heart failure – beta blockers and ACE inhibitors. "This is quite remarkable for this disease," Liao says.

Heart failure occurs when the heart can’t pump enough blood to meet the body’s needs. It’s associated with inflammation and an imbalance of hormones released by the body’s defense system, which tends to overcompensate for the patient’s poor heart function. "Because statins improve blood vessel function and suppress the inflammatory process, we believed that statins might improve heart function and the neurohormonal imbalance found in most forms of chronic heart failure," Liao explains.

To exclude statins’ well-known cholesterol-lowering properties, which may improve heart failure caused by coronary artery disease, the researchers limited the study to patients with idiopathic dilated cardiomyopathy, meaning their heart failure was due to viral or genetic causes rather than to blockage of heart vessels caused by high cholesterol. The heart failure patients in this study, therefore, are rather young (53 to 55) and otherwise healthy patients who often qualify for heart transplants, he says. Because their heart failure isn’t caused by coronary artery disease, these patients often don’t experience the chest pain (angina) associated with narrowed coronary arteries. Instead, they often experience shortness of breath and fatigue. There are about 550,000 new cases of heart failure per year and about 15 percent of them are non ischemic, Liao says.

Researchers studied 51 patients in Japan, where lead author Koichi Node, M.D., Ph.D., is a professor of medicine in the cardiovascular division at Saga Medical School, Saga, Japan. Participants received either 5 milligrams (mg) of the statin drug simvastatin for four weeks followed by 10 mg of it for 10 weeks, or a placebo. The standard U.S. and European dose of simvastatin for lowering cholesterol is 40 mg.

Because of the small dose, average total cholesterol fell only modestly for the statin users, from 221 mg/deciliter (mg/dL) to 201 mg/dL.

Patients treated with simvastatin reached a better New York Heart Association (NYHA) functional level (from 2.39 to 2.04) than those on placebo (from 2.36 to 2.32). The NYHA levels gauge heart function on a scale from I to IV with IV being severe heart failure that keeps a patient bedridden because any exertion brings on breathlessness and fatigue. In the statin group, 39.1 percent of patients had an improved functional class, 56.6 percent remained unchanged and 4.3 percent worsened. In the placebo group, only 16 percent improved, 72 percent remained the same and 12 percent deteriorated.

The left ventricular ejection fraction, a measure of heart function, rose from 34 percent to 41 percent in the statin group, but stayed the same in the placebo group, he adds.

"These improvements are significant given that these patients had only moderate disease and were treated for only 14 weeks," Liao says. "This opens up a new treatment strategy for patients with heart failure, regardless of their cholesterol levels." However, researchers caution that larger studies with hard endpoints are needed before statins can be recommended to treat patients with this form of chronic heart failure.

Other Co-authors are Masahi Fujita, M.D.; Masafumi Kitakaze, M.D., Ph.D.; and Masatsugu Hori, M.D.

Carole Bullock | EurekAlert!
Further information:

More articles from Studies and Analyses:

nachricht Diagnoses: When Are Several Opinions Better Than One?
19.07.2016 | Max-Planck-Institut für Bildungsforschung

nachricht High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Oasis of life in the ice-covered central Arctic

24.10.2016 | Earth Sciences

‘Farming’ bacteria to boost growth in the oceans

24.10.2016 | Life Sciences

Light-driven atomic rotations excite magnetic waves

24.10.2016 | Physics and Astronomy

More VideoLinks >>>